This is not the most recent version of the article. View current version (26 JUL 2013)

Intervention Review

Insulin and oral agents for managing cystic fibrosis-related diabetes

  1. Gary M Onady1,*,
  2. Adrienne Stolfi2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 20 JUL 2005

Assessed as up-to-date: 3 NOV 2008

DOI: 10.1002/14651858.CD004730.pub2


How to Cite

Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004730. DOI: 10.1002/14651858.CD004730.pub2.

Author Information

  1. 1

    Wright State University, Boonshoft School of Medicine, Dayton, Ohio, USA

  2. 2

    Children's Medical Center, Department of Pediatrics, Dayton, Ohio, USA

*Gary M Onady, Boonshoft School of Medicine, Wright State University, Room 105, Medical Sciences Building, 3640 Colonel Glenn Highway, Dayton, Ohio, OH 45435, USA. gmonady@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 JUL 2005

SEARCH

This is not the most recent version of the article. View current version (26 JUL 2013)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Enza Mozzillo, Adriana Franzese, Giuliana Valerio, Angela Sepe, Ilaria De Simone, Gianfranco Mazzarella, Pasqualina Ferri, Valeria Raia, One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements, Pediatric Diabetes, 2009, 10, 3
  2. You have free access to this content2
    Stephen MP O’Riordan, Paul D Robinson, Kim C Donaghue, Antoinette Moran, Management of cystic fibrosis-related diabetes, Pediatric Diabetes, 2008, 9, 4pt1
  3. 3
    Gary M Onady, Adrienne Stolfi, Insulin and oral agents for managing cystic fibrosis-related diabetes, The Cochrane Library,